Advances in Liquid Biopsy for Diagnosis of Bladder Cancer

키워드

참고문헌 (103)

1. Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
2. Tran L, "Advances in bladder cancer biology and therapy", Nat Rev Cancer, 21, pp.104~121 (2021)
3. Cumberbatch MGK, "Repeat transurethral resection in non-muscleinvasive bladder cancer : a systematic review", Eur Urol, 73, pp.925~933 (2018)
4. Zhu CZ, "A review on the accuracy of bladder cancer detection methods", J Cancer, 10, pp.4038~4044 (2019)
5. Babjuk M, "European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer(TaT1 and Carcinoma In Situ)-2019 Update", Eur Urol, 76, pp.639~657 (2019)
6. Svatek RS, "The economics of bladder cancer : costs and considerations of caring for this disease", Eur Urol, 66, pp.253~262 (2014)
7. Kim J, "Advances in urinary biomarker discovery in urological research", Investig Clin Urol, 61(Suppl 1), pp.S8~S22 (2020)
8. He D, "Nuclear matrix proteins as structural and functional components of the mitotic apparatus", Int Rev Cytol, 162B, pp.1~74 (1995)
9. Cho YH, "Bladder cancer", pp.599~612 (2018), Academic Press
10. Hatzichristodoulou G, "Nuclear matrix protein 22 for bladder cancer detection : comparative analysis of the BladderChek® and ELISA", Anticancer Res, 32, pp.5093~5097 (2012)
11. Wang Z, "Evaluation of the NMP22 BladderChek test for detecting bladder cancer : a systematic review and meta-analysis", Oncotarget, 8, pp.100648~100656 (2017)
12. Lokeshwar VB, "Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests", Cancer, 95, pp.61~72 (2002)
13. Sarosdy MF, "Improved detection of recurrent bladder cancer using the Bard BTA stat Test", Urology, 50, pp.349~353 (1997)
14. Pode D, "Noninvasive detection of bladder cancer with the BTA stat test", J Urol, 161, pp.443~446 (1999)
15. Ellis WJ, "Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group", Urology, 50, pp.882~887 (1997)
16. Mian C, "Immunocyt : a new tool for detecting transitional cell cancer of the urinary tract", J Urol, 161, pp.1486~1489 (1999)
17. Allard P, "Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder", Clin Cancer Res, 1, pp.1195~1202 (1995)
18. Têtu B, "ImmunoCyt", uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma, 2005, pp.18, 83~89
19. Pfister C, "Immunocyt test improves the diagnostic accuracy of urinary cytology : results of a French multicenter study", J Urol, 169, pp.921~924 (2003)
20. Laudadio J, "Fluorescence in situ hybridization for detecting transitional cell carcinoma : implications for clinical practice", BJU Int, 96, pp.1280~1285 (2005)
21. Friedrich MG, "Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer", BJU Int, 92, pp.911~914 (2003)
22. Hajdinjak T, "UroVysion FISH test for detecting urothelial cancers : meta-analysis of diagnostic accuracy and comparison with urinary cytology testing", Urol Oncol, 26, pp.646~651 (2008)
23. Dimashkieh H, "Evaluation of urovysion and cytology for bladder cancer detection : a study of 1835 paired urine samples with clinical and histologic correlation", Cancer Cytopathol, 121, pp.591~597 (2013)
24. Vasseur A, "Clinical utility of circulating tumor cells : an update", Mol Oncol, 15, pp.1647~1666 (2021)
25. Li S, "Blood-based liquid biopsy : insights into early detection, prediction, and treatment monitoring of bladder cancer", Cell Mol Biol Lett, 28, pp.28~ (2023)
26. Qi F, "Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance", Tumour Biol, 35, pp.7217~7223 (2014)
27. Khetrapal P, "The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer : a systematic review", Cancer Treat Rev, 66, pp.56~63 (2018)
28. Gires O, "Expression and function of epithelial cell adhesion molecule EpCAM : where are we after 40 years?", Cancer Metastasis Rev, 39, pp.969~987 (2020)
29. Brunner A, "EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder", J Clin Pathol, 61, pp.307~310 (2008)
30. van der Fels CAM, "epCAM Expression in lymph node metastases of urothelial cell carcinoma of the bladder : a pilot study", Int J Mol Sci, 18, pp.1802~ (2017)
31. Rink M, "The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder", World J Urol, 37, pp.1785~1799 (2019)
32. Soria F, "Molecular markers in bladder cancer", World J Urol, 37, pp.31~40 (2019)
33. Gazzaniga P, "Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer", Int J Cancer, 135, pp.1978~1982 (2014)
34. Abrahamsson J, "Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder : association with tumor stage, lymph node metastases, FDG-PET findings, and survival", Urol Oncol, 35, pp.606~ (2017)
35. Haga N, "Increase in circulating tumor cells in invasive bladder cancer after transurethral resection of bladder tumor", Anticancer Res, 40, pp.4299~4307 (2020)
36. Song P, "Limitations and opportunities of technologies for the analysis of cellfree DNA in cancer diagnostics", Nat Biomed Eng, 6, pp.232~245 (2022)
37. Wang XS, "Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer : a meta-analysis", Am J Transl Res, 10, pp.1935~1948 (2018)
38. Oxnard GR, "Genomic analysis of plasma Cell-Free DNA in patients with cancer", JAMA Oncol, 3, pp.740~741 (2017)
39. Husain H, "Cancer DNA in the circulation : the liquid biopsy", JAMA, 318, pp.1272~1274 (2017)
40. Jordahl KM, "Genome-wide dna methylation in prediagnostic blood and bladder cancer risk in the women’s health initiative", Cancer Epidemiol Biomarkers Prev, 27, pp.689~695 (2018)
41. Valenzuela MT, "Assessing the use of p16(INK4a)promoter gene methylation in serum for detection of bladder cancer", Eur Urol, 42, pp.622~628 (2002)
42. Ellinger J, "Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer", J Urol, 179, pp.346~352 (2008)
43. Millis SZ, "Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin", Clin Genitourin Cancer, 13, pp.e37~e49 (2015)
44. Vandekerkhove G, "Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer", Clin Cancer Res, 23, pp.6487~6497 (2017)
45. Patel KM, "Association of plasma and urinary mutant dna with clinical outcomes in muscle invasive bladder cancer", Sci Rep, 7, pp.5554~ (2017)
46. Vandekerkhove G, "Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer", Nat Commun, 12, pp.184~ (2021)
47. Green EA, "Clinical utility of cell-free and circulating tumor dna in kidney and bladder cancer : a critical review of current literature", Eur Urol Oncol, 4, pp.893~903 (2021)
48. Mai S, "Upregulation of circ_PVT1 and circ_001569 indicate unfavorable prognosis in colorectal cancer", Ann Clin Lab Sci, 51, pp.55~60 (2021)
49. Jiang X, "Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer", Int J Cancer, 136, pp.854~862 (2015)
50. Feng Y, "miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer", J Exp Clin Cancer Res, 33, pp.67~ (2014)
51. Motawi TK, "Circulating microRNAs, miR-92a, miR-100 and miR-143, as non-invasive biomarkers for bladder cancer diagnosis", Cell Biochem Funct, 34, pp.142~148 (2016)
52. Usuba W, "Circulating miRNA panels for specific and early detection in bladder cancer", Cancer Sci, 110, pp.408~419 (2019)
53. Marín-Aguilera M, "Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer", Urology, 79, pp.240~ (2012)
54. Gazzaniga P, "Detection of epidermal growth factor receptor mRNA in peripheral blood : a new marker of circulating neoplastic cells in bladder cancer patients", Clin Cancer Res, 7, pp.577~583 (2001)
55. "Actas Urol Esp", 2011, 127~136
56. Caby MP, "Exosomal-like vesicles are present in human blood plasma", Int Immunol, 17, pp.879~887 (2005)
57. Georgantzoglou N, "Extracellular vesicles as biomarkers carriers in bladder cancer : diagnosis, surveillance, and treatment", Int J Mol Sci, 22, pp.2744~ (2021)
58. Kalluri R, "The biology, function, and biomedical applications of exosomes", Science, 367, pp.eaau6977~ (2020)
59. Wang J, "Determination of serum exosomal h19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis", Med Sci Monit, 24, pp.9307~9316 (2018)
60. Xue M, "Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-UCA1", Mol Cancer, 16, pp.143~ (2017)
61. Zheng R, "Exosometransmitted long non-coding RNA PTENP1 suppresses bladder cancer progression", Mol Cancer, 17, pp.143~ (2018)
62. Zhang S, "Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer", J Cell Mol Med, 23, pp.1396~1405 (2019)
63. Yin X, "Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells", Cell Biol Int, 44, pp.958~965 (2020)
64. Yan L, "MiR-4644 is upregulated in plasma exosomes of bladder cancer patients and promotes bladder cancer progression by targeting UBIAD1", Am J Transl Res, 12, pp.6277~6289 (2020)
65. Li Q, "The role of exosomal miR-375-3p : a potential suppressor in bladder cancer via the Wnt", β-catenin pathway, 2020, pp.34, 12177~12196
66. Cai X, "Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1", Cancer Med, 9, pp.6009~6019 (2020)
67. Sabo AA, "Small non-coding RNA profiling in plasma extracellular vesicles of bladder cancer patients by next-generation sequencing : expression levels of miR-126-3p and piR-5936 increase with higher histologic grades", Cancers(Basel), 12, pp.1507~ (2020)
68. Kumar A, "Challenges and opportunities in cancer metabolomics", Proteomics, 19, pp.e1900042~ (2019)
69. Graça G, "Exploring cancer metabolism : applications of metabolomics and metabolic phenotyping in cancer research and diagnostics", Adv Exp Med Biol, 1219, pp.367~385 (2020)
70. Bansal N, "Low-and high-grade bladder cancer determination via human serum-based metabolomics approach", J Proteome Res, 12, pp.5839~5850 (2013)
71. Tan G, "Three serum metabolite signatures for diagnosing low-grade and highgrade bladder cancer", Sci Rep, 7, pp.46176~ (2017)
72. Ossoliński K, "Metabolomic and elemental profiling of blood serum in bladder cancer", J Pharm Anal, 12, pp.889~900 (2022)
73. Bansal N, "Low-and highgrade bladder cancer appraisal via serum-based proteomics approach", Clin Chim Acta, 436, pp.97~103 (2014)
74. Bansal N, "Serumbased protein biomarkers of bladder cancer : a pre-and post-operative evaluation", J Pharm Biomed Anal, 124, pp.22~25 (2016)
75. Elamin AA, "A specific blood signature reveals higher levels of S100A12 : a potential bladder cancer diagnostic biomarker along with urinary engrailed-2 protein detection", Front Oncol, 9, pp.1484~ (2020)
76. Allione A, "MMP23B expression and protein levels in blood and urine are associated with bladder cancer", Carcinogenesis, 39, pp.1254~1263 (2018)
77. López-Cortés R, "Blood-based protein biomarkers in bladder urothelial tumors", J Proteomics, 247, pp.104329~ (2021)
78. Roperch JP, "A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients-Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer(NMIBC)", BMC Med Genet, 21, pp.112~ (2020)
79. Dahmcke CM, "A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria", Eur Urol, 70, pp.916~919 (2016)
80. van Kessel KE, "Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy", J Urol, 197(3 Pt 1), pp.590~595 (2017)
81. Catto JW, "Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma", J Clin Oncol, 23, pp.2903~2910 (2005)
82. Esteller M, "Epigenetics in cancer", N Engl J Med, 358, pp.1148~1159 (2008)
83. Kandimalla R, "DNA methylationbased biomarkers in bladder cancer", Nat Rev Urol, 10, pp.327~335 (2013)
84. van der Heijden AG, "Urine cell-based DNA methylation classifier for monitoring bladder cancer", Clin Epigenetics, 10, pp.71~ (2018)
85. Renard I, "Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylationspecific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples", Eur Urol, 58, pp.96~104 (2010)
86. Su SF, "A panel of three markers hyper-and hypomethylated in urine sediments accurately predicts bladder cancer recurrence", Clin Cancer Res, 20, pp.1978~1989 (2014)
87. Hauser S, "Serum DNA hypermethylation in patients with bladder cancer : results of a prospective multicenter study", Anticancer Res, 33, pp.779~784 (2013)
88. Feber A, "UroMark-a urinary biomarker assay for the detection of bladder cancer", Clin Epigenetics, 9, pp.8~ (2017)
89. Springer SU, "Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy", Elife, 7, pp.e32143~ (2018)
90. Beukers W, "FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study", J Urol, 197, pp.1410~1418 (2017)
91. Birkenkamp-Demtröder K, "Genomic alterations in liquid biopsies from patients with bladder cancer", Eur Urol, 70, pp.75~82 (2016)
92. Togneri FS, "Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA", Eur J Hum Genet, 24, pp.1167~1174 (2016)
93. Ou Z, "Detection of bladder cancer using urinary cell-free DNA and cellular DNA", Clin Transl Med, 9, pp.4~ (2020)
94. Chauhan PS, "Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients", NPJ Precis Oncol, 7, pp.6~ (2023)
95. Babu S, "Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia", Mod Pathol, 32, pp.717~724 (2019)
96. Fouad H, "MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer", J Biochem Mol Toxicol, 33, pp.e22275~ (2019)
97. Zhou BF, "Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples", Oncotarget, 7, pp.41703~41714 (2016)
98. Huang H, "Combination of urine exosomal mRNAs and lncRNAs as novel diagnostic biomarkers for bladder cancer", Front Oncol, 11, pp.667212~ (2021)
99. Lee DH, "Urinary exosomal and cell-free DNA detects somatic mutation and copy number alteration in urothelial carcinoma of bladder", Sci Rep, 8, pp.14707~ (2018)
100. Zhou X, "Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer", Mol Ther Methods Clin Dev, 22, pp.360~376 (2021)
101. Lin JY, "Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics", BMC Bioinformatics, 22, pp.305~ (2021)
102. Wang R, "Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS", BMC Cancer, 22, pp.214~ (2022)
103. Zhou Y, "Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method", Oncotarget, 8, pp.20719~20728 (2017)

관련 논문AI추천